Two Onc Docs
This is Sam and Karine, and we are Two Onc Docs! We both graduated from our Heme/Onc fellowships in 2021 and became board certified in both Hematology and Oncology. Our mission with Two Onc Docs is to create short board review episodes that you can listen to on your drive to work, while you make your morning coffee, or between pages on call. This is intended to be a supplement to other established board studying resources for busy trainees. *This podcast is intended to be an educational resource for health care providers.*
Two Onc Docs
ASCO 2024 Plenary: NADINA Trial Neoadjuvant Ipi/Nivo vs Adjuvant Nivo for Resectable Stage III Melanoma
•
Season 3
•
Episode 25
This week’s episode will be discussing updates from ASCO 2024 next with the practice changing NADINA trial presented on the Sunday of ASCO by Dr. Christian Blank during the plenary sessions: A multicenter, randomized, phase 3 trial comparing the efficacy of neoadjuvant ipilimumab plus nivolumab with standard adjuvant nivolumab in macroscopic resectable stage III melanoma. We discuss the staging and prior standard of treatment for locally advanced melanoma, key findings from NADINA, and how these data may impact clinical practice.